Analysts Offer Insights on Healthcare Companies: Wuxi Biologics (Cayman) (OtherWXIBF) and Generation Bio (GBIO)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Wuxi Biologics (Cayman) (WXIBF – Research Report) and Generation Bio (GBIO – Research Report).

Wuxi Biologics (Cayman) (WXIBF)

Jefferies analyst Chris Lui maintained a Buy rating on Wuxi Biologics (Cayman) yesterday and set a price target of HK$42.00. The company’s shares closed last Friday at $2.02, close to its 52-week low of $1.63.

According to TipRanks.com, Lui ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -16.4% and a 34.3% success rate. Lui covers the Healthcare sector, focusing on stocks such as The United Laboratories International Holdings, China Traditional Chinese Medicine Holdings Co, and Ping An Healthcare and Technology Company.

Currently, the analyst consensus on Wuxi Biologics (Cayman) is a Moderate Buy with an average price target of $3.46.

See Insiders’ Hot Stocks on TipRanks >>

Generation Bio (GBIO)

In a report released yesterday, Brendan Smith from TD Cowen downgraded Generation Bio to Hold. The company’s shares closed last Monday at $2.84.

According to TipRanks.com, Smith is a 1-star analyst with an average return of -16.0% and a 33.3% success rate. Smith covers the Healthcare sector, focusing on stocks such as Denali Therapeutics, Halozyme, and Novavax.

Currently, the analyst consensus on Generation Bio is a Moderate Buy with an average price target of $8.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.